Home›Trial›NCT05648591
NCT05648591Phase 4RECRUITING

Safety and Tolerability of Open-Labeled Iloperidone in Adolescents

Study Summary

To evaluate the safety and tolerability of iloperidone in adolescent patients with schizophrenia or bipolar I disorder for up to 52 weeks of treatment.

Conditions
SchizophreniaBipolar I Disorder
Interventions / Drugs
Iloperidone
View on ClinicalTrials.gov ↗
Sponsor
VNDA
Vanda Pharmaceuticals
Neuroscience
D41/100
Study Details
Enrollment100 participants
Primary Completion—
Lead SponsorVanda Pharmaceuticals
Data Retrieved2026-04-11 04:31:05.188485+00:00
What This Trial Means for Biotech Investors
Trial Phase Context

This trial phase represents an early or specialized stage of clinical development.

Status & Expected Data

Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.

Enrolled: 100 participants
Sponsor Catalyst Profile

Vanda Pharmaceuticals (VNDA) is the sponsoring company for this trial. BiotechSign currently grades this company D (41/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

VNDA Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.